in ~30% of neuronal soma and dendrites, in which they appear skein-like, but over time they form condensed accumulations that resemble Lewy bodies. Neuron death is negligible before 14 d after adding the PFFs. This permits the careful examination of α-syn aggregates from their initial early formation to their spread throughout the neuron, and ultimately to the point of neuron death; it further allows the study of how neuronal function may be perturbed at each of these stages. For example, calcium imaging experiments reveal major defects in neuronal synchronization at early time points when only small aggregates are present in axons 15 . In addition, one of the most predominant phenotypes is the increased expression of canonical autophagy markers 19 . However, although mature α-syn aggregates associate with components of autophagy machinery, they cannot be efficiently degraded by this pathway. Furthermore, mitochondrial oxidant stress contributes to Parkinson's disease pathogenesis, and it can be measured in dopaminergic neurons from the substantia nigra pars compacta by the expression of mitochondrially targeted redox-sensitive GFP expressed under control of a tyrosine hydroxylase (TH) promoter (TH-mito-roGFP) 20 . The use of live-cell imaging of dopamine primary neurons derived from mice expressing TH-mito-roGFP demonstrates that the presence of α-syn aggregates markedly increases mitochondrial oxidant stress, particularly in the soma and dendrites. Interestingly, the mitochondrial oxidant stress probably derives from increased lysosomal oxidase activity.
A crucial aspect of this model is that none of the phenotypes described above occur when PFFs are added to primary neurons from α-syn knockout mice. For example, the PFFs themselves are not phosphorylated, and therefore when they are added to α-syn knockout neurons there is no phosphorylated α-syn (p-α-syn) visible by immunofluorescence or immunoblotting 15 . Furthermore, the addition of fibrils to neurons from α-syn knockout mice does not cause cell death or changes in neuronal synchronous firing, excitation or connectivity. Thus, the pathological phenotypes are caused by 'seeded' corruption of endogenous α-syn, probably through both a loss of normal α-syn function and gains of toxic functions from the accumulation of the Lewy neurite and Lewy body-like inclusions, rather than through exposure to the synthetic fibrils themselves.
Overall, this model provides researchers with the opportunity to understand how the presence of neuronal α-syn aggregates contributes to disease pathogenesis at cellular and subcellular level ( Fig. 1) with well-defined temporal and spatial resolution.
Applications of the protocol
There are many other advantages afforded by this model in addition to those mentioned above. First, α-syn aggregation occurs in normal wild-type neurons expressing endogenous α-syn (i.e., it does not require overexpression of wild-type or mutant α-syn) 15 . Thus, researchers can potentially understand the effect of any gene of interest on α-syn aggregate formation using knockout mice or transgenic mice. Second, α-syn aggregation occurs in primary neurons derived from hippocampus, cortex, midbrain and other brain regions, and thus the impact of these aggregates on diverse neuronal populations and neuronal subtypes could be examined 15, 20, 21 . In addition, it provides spatial resolution to allow high-resolution microscopy and/or live-cell imaging, and thus future studies can elucidate the cell biological and physiologic effect of α-syn aggregate formation. For example, transfection of fluorescent probes of localization and function of distinct organelles can be accomplished using various published protocols [22] [23] [24] . Furthermore, this method can potentially be used in conjunction with established methods in which neurons are compartmentalized (e.g., in microfluidic or Campenot chambers) to understand how α-syn aggregates may spread from neuron to neuron, which has recently been shown to contribute to disease progression 25, 26 . Finally, another future potential application is the screening of putative therapeutics to prevent the formation of these aggregates.
Limitations of the protocol
In cultures from nontransgenic mice, there is a 2-4-d lag phase before insoluble, phosphorylated aggregates appear. Thus, any compounds tested during this lag phase using this model must not be detrimental to neuron health when used over this time course. However, it may be possible to reduce the concentrations of test compounds such that they remain effective but do not lead to neuron death. Furthermore, this lag phase can be reduced by the overexpression of α-syn.
Experimental design
Primary neuron culture. Although we provide some information here regarding culturing of primary neurons, these methods have been presented in detail elsewhere, and we reference these protocols for full details 23, 27, 28 . Other laboratories have reported strong PFF seeding using their own culturing methods 20, 21 . Recommended plating densities are provided for culturing neurons, as we have found that the efficiency of aggregate formation depends on synaptic densities; the higher the density of the cultures, the more aggregates are produced. The procedure describes culture of hippocampal neurons from one pregnant C57BL/6 mouse with ~6-8 embryonic day (E)16-E17 embryos. We generally perform experiments using hippocampal neurons from nontransgenic mice because α-syn aggregates are found in the hippocampus in diseased brains and correlate with cognitive impairments [29] [30] [31] ; the morphological and physiological properties of these neurons in culture have been well defined 32 ; and we can obtain enough neurons for both imaging and biochemical studies. Seeded α-syn inclusions also develop in primary neurons from cortex and tyrosine hydroxylase-positive neurons from cultured midbrain 15, 20 . However, the presence of inclusions may depend on the subtype of neuron, for example, glutamic acid decarboxylase-positive inhibitory neurons do not form inclusions because of low to no expression of α-syn in these neurons 21 .
PFFs. Storage of the PFFs is another crucial factor in the effectiveness of the protocol. Once they are generated, we recommend dividing the PFFs into aliquots and storing them at −80 °C, because we and others 33 have observed that storage at 4 °C results in loss of activity. Sonication with a probe tip sonicator is another crucial step in this protocol to generate small seeds (Supplementary Video 1 and Fig. 2 ). We recommend adding PFFs at 5-10 days in vitro (DIV) because α-syn is only expressed at mature synapses 34 . PFFs can also be added at later time points, and pathology will proceed more quickly because higher levels of α-syn are expressed at presynaptic terminals. However, because neurons in culture typically only last ~21-31 d in culture in general, we do not recommend adding PFFs at too late a time point because the neurons (including control neurons) may begin to die before the aggregates spread throughout the neuron, thus adding a confounding factor. In addition, we provide our recommended concentrations of PFFs to add to neurons. However, we suggest testing a range of concentrations to determine which concentration is best for each researcher's particular assay.
Choice of controls.
Here we describe the use of PBS as a control.
Other controls may include treatment of the neurons with α-syn monomer, which does not produce α-syn aggregates. However, given the propensity for α-syn to aggregate, it is important to centrifuge the monomer after thawing (benchtop ultracentrifuge, 100,000g, 1 h at room temperature (20-25 °C)) to remove any small fibrils that may have formed, and to use only the resulting supernatant. As mentioned above, cultures from α-syn knockout mice can be used as a control to confirm that phenotypes result from aggregates that are formed from endogenously expressed α-syn and not from the addition of PFFs.
PFFs before sonication PFFs after sonication 
MaterIals

REAGENTS
Recombinant α-syn, which can be purified as previously published [35] [36] [37] [38] [39] (the purification is also summarized in Box 1). We recommend the purification of α-syn because it can be prepared without a tag that may interfere with fibrillization (commercial sources of α-syn often contain a poly-His tag), high protein concentrations (up to 30 mg/ml) can be obtained and the final buffer can be controlled. In addition, we have successfully used both recombinant human and mouse α-syn 15 . The advantage of human α-syn is the availability of human-specific α-syn antibodies that allow the exogenously added fibrils to be specifically identified ! cautIon Although the safety of handling recombinant α-syn has not been assessed, we recommend using personal protective equipment and biohazard safety level 2 (BSL2 Antibodies specific for α-syn phosphorylated at Ser129. These are sold by many companies. We have found the following antibodies to work well: Covance, cat. no. MMS-5091; MJFR1, Epitomics, cat. no. 138501  crItIcal For both immunofluorescence and immunoblotting, perform a dilution series to determine minimal concentration antibody needed for signal in PFF-treated neurons and minimal signal in PBS-treated neurons. Depending on the antibody, the dilutions can range from 1:1,000 up to 1:10,000.  crItIcal This pore size is important because of the small size of α-syn.
• 
The methods for purifying α-syn have been published in detail in several publications [35] [36] [37] [38] [39] . Here we describe our protocol for purifying human full-length α-syn (NM_000345) or mouse full-length α-syn (NM_001042451). The final goal is to obtain a high concentration of untagged α-synuclein in a final buffer composed of Tris and NaCl.
expression in Escherichia coli 1. Clone α-syn into the ampicillin-resistant bacterial expression vector pRK172. Expression of α-syn from this plasmid does not require induction by IPTG, and so you will likely have to modify your protocol if you are using another vector. Plating medium Combine Neurobasal medium, 1× B27 from a 50× stock, 1× GlutaMAX from a 100× stock, 50 U/ml penicillin and 50 µg/ml streptomycin (1:200 dilution from a 100× stock) and 10% (vol/vol) FBS. Filter-sterilize the solution and store it at 4 °C for no longer than 3 weeks. Neuronal medium Combine Neurobasal medium, 1× B27 from a 50× stock, 1× GlutaMAX from a 100× stock, 50 U/ml penicillin and 50 µg/ml streptomycin (1:200 dilution from a 100× stock). Filter-sterilize the solution and store it at 4 °C for no longer than 3 weeks. HBSS To HBSS, add 6 ml of 1 M HEPES (pH 7.4), 3 ml of 50 U/ml penicillin and 50 µg/ml streptomycin and 6 ml of 100 mM pyruvic acid. Bring the final
volume to 500 ml with the remaining HBSS, and add 100 ml of water (final volume 600 ml). Filter-sterilize the solution and store it at 4 °C for no longer than 3 weeks. Papain solution Make the solution freshly before starting dissection. For tissue from 6-8 pups, make 10 ml. Add papain to HBSS (above) to a final concentration of 20 U/ml, 2 mg l-cysteine (22 µl of 500 mM EDTA, pH 8.0). Incubate the mixture with shaking at room temperature to allow papain to dissolve. PDL-coated coverslips in culture dish for immunofluorescence Dissolve PDL at a concentration of 2 mg/ml in borate buffer. Filter-sterilize the solution. Make 2-ml aliquots in polystyrene tubes and freeze them at −20 °C. These aliquots can be stored indefinitely. PDL-coated culture dishes for immunoblot analysis Place coverslips in 95% (vol/vol) ethanol. Put one coverslip each in individual wells of a 24-well plate and rinse twice with 0.5 ml of sterile water. Alternatively, multiple coverslips can be placed in a six-well or 6-cm dish. Coat the coverslips with 0.1 mg/ml PDL for 1.5 h (or overnight) at 37 °C (ensure that the coverslips are completely covered with solution). Rinse twice with water followed by neuronal plating medium. Store the coverslips in a 37 °C tissue culture incubator in plating medium for no longer than 1 week. Before use, add sterile water in between wells to maintain humidity and to prevent medium evaporation. Coat the wells of 6-or 12-well or 6-cm dishes as described above for coverslips. 4% (wt/vol) Paraformaldehyde/4% (wt/vol) sucrose/PBS For 50 ml in PBS, pipette 10 ml of 20% paraformaldehyde into ~40 ml of PBS, add 2 g of sucrose and mix it until it dissolves. Bring the volume to 50 ml with PBS. This solution works best if it is used at room temperature, although others report optimal results when it is warmed to 37 °C. This solution can be stored at 4 °C, protected from light, for 1 week.
4% (wt/vol) Paraformaldehyde/4% (wt/vol) sucrose/1% (vol/vol)
TX-100/PBS Make 4% (wt/vol) paraformaldehyde/4% (wt/vol) sucrose as described above, but add 1 ml of 10% (vol/vol) TX-100/PBS and then bring it to the final volume using PBS. This solution can be stored at 4 °C, protected from light, for 1 week. Permeabilization buffer This buffer contains 3% (wt/vol) BSA and 0.1% (vol/vol) TX-100 in PBS. For 10 ml, add 3 ml of 10% (wt/vol) BSA/PBS and 100 µl of 10% (vol/vol) TX-100/PBS and bring the final volume to 10 ml with PBS. Make this solution freshly. Blocking buffer Blocking buffer is 3% (wt/vol) BSA in PBS. For 10 ml, add 3 ml of 10% (wt/vol) BSA/PBS and bring the volume to 10 ml with PBS. Freshly make this buffer. Dilute primary and secondary antibodies in blocking buffer on the day of use. TBS TBS contains 50 mM Tris and 150 mM NaCl (pH 7.4). It can be stored indefinitely at room temperature. TBS/T TBS/T is TBS with 0.2% (vol/vol) Tween-20. It can be stored indefinitely at 4 °C. Protease inhibitors 1,000× stock contains 1 mg/ml pepstatin, 1 mg/ml leupeptin, 1 mg/ml TPCK, 1 mg/ml TLCK, 1 mg/ml trypsin inhibitor and 0.1 M EDTA, all from Sigma-Aldrich; make aliquots and store them at −20 °C. Phosphatase inhibitors 100× stock contains 200 mM imidazole, 100 mM NaF and 100 mM Na-orthovanadate; make aliquots and store them at −20 °C. Ice-cold 1% (vol/vol) TX-100 in TBS with protease and phosphatase inhibitors (make it on the day of use) For 10 ml, mix 1 ml of 10% (vol/vol) TX-100 in TBS, bring it to 10 ml with TBS, dilute protease inhibitors 1:1,000, dilute phosphatase inhibitors 1:100, vortex the mixture and keep it on ice. Room temperature 2% (wt/vol) SDS in TBS with protease and phosphatase inhibitors (make it on the day of use) For 1 ml, mix 200 µl of 10% (wt/vol) SDS, 800 µl of TBS, dilute protease inhibitors (1:1,000) and dilute phosphatase inhibitors (1:100); vortex the mixture and keep it at room temperature to prevent precipitation of SDS. 40, 41 . Decontaminate PFFs or any spills with a final concentration of 1 N NaOH or 20,000 p.p.m. bleach (two parts 5.25% (wt/vol) household bleach to three parts water) for 1 h. Make NaOH or bleach solutions freshly daily. Use disposable, absorbent pads whenever possible.
SDS-PAGE running buffer
1|
Rapidly thaw purified α-syn monomer in a 1.5-ml microcentrifuge tube in a 37 °C water bath until small ice cubes are visible. Place the tube on ice until it is completely thawed.
2|
Centrifuge the tube at 100,000g at 4 °C for 60 min to pellet any aggregated material. Remove the supernatant to use for the generating PFFs.
3| Dilute the supernatant from
Step 2 in PBS in a new, sterile 1.5-ml microcentrifuge tube to a final volume of 500 µl and a final concentration of 5 mg/ml.
4|
Place the tube in a Thermomixer that is set inside a standard laboratory 37 °C incubator (this helps prevent condensation, which could affect fibril concentration). 
5|
8|
Centrifuge the tube at 100,000g for 60 min at room temperature.
9|
Carefully remove the supernatant (20 µl) and transfer it to a new tube. Add 20 µl of 2× Laemmli buffer.
10|
Suspend the pellet in 20 µl of PBS, and centrifuge it again at 100,000g for 30 min. Discard the supernatant.
11|
Suspend the pellet in 20 µl of PBS, and add 20 µl of 2× Laemmli buffer to this fraction.
12| Load 15 µl of the supernatant from Step 9 and pellet from Step 11 onto a 4-20% (wt/vol) acrylamide gel with a 15-well comb and perform SDS-PAGE. Perform Coomassie staining and destaining. There should be approximately equivalent amounts of α-syn (typically runs above the 15-kDa marker) in the supernatant and pellet (Fig. 3) , or more in the pellet. If there is more α-syn in the supernatant than in the pellet, the PFFs will be less efficient. If this is the case, check the pH of the PBS, as we found this to be crucial in PFF formation.
? trouBlesHootInG  pause poInt PFF activity can be determined at any time point during the storage of PFFs.
culturing neurons • tIMInG ~8 h 13| Calculate the amount of plating medium and neuronal medium needed (20 ml for rinses, 0.5 ml for each well of a 24-well dish and 2 ml for each well of a six-well dish). Pipette the plating medium and neuronal medium into separate T75 sterile tissue culture flasks, label the flasks clearly and place them in the tissue culture CO 2 incubator for 2-24 h. This step will equilibrate the pH of the medium, and it should be slightly orange-pink in color.
14|
Dissect the hippocampi as previously described using cold Hibernate-E 27,28 .
15|
Place the dissected tissue in a 15-ml Falcon tube with 10 ml of Hibernate-E on ice.
 pause poInt Tissue is stable on ice for up to 8 h. We have kept tissue on ice for 24 h, and successfully obtained viable neurons, but more cell death was observed.
16|
Rinse the tissue twice with HBSS. Remove the final HBSS (can leave ~1 ml).
17| Filter-sterilize papain solution using a 0.20-µm syringe filter, and add 10 ml to the tissue. Incubate the tissue in a tissue culture incubator for 30-60 min.
18| Place the tube with tissue in a culture hood, and allow the tissue to sink to the bottom of the tube. Carefully remove the papain solution (the tissue is very sticky).
19| Add 50 µl of DNase solution to 10 ml of plating solution. Add this to the tissue. The tissue will now easily sink to the bottom of the tube. Rinse it one more time with plating medium.
20|
Rinse the tissue twice with 10 ml of HBSS. Remove the final HBSS so that ~1 ml remains.
21|
Triturate the tissue ten times.
22| Add 5 ml of HBSS and filter it through a 40-mm nylon mesh cell strainer. Perform a cell count.
23|
Plate the neurons as follows and place them in the tissue culture incubator. 24| Between 2 and 18 h after plating, completely change the plating medium to neuronal medium. We use slightly more medium (1 ml for each well of a 24-well plate and 2.5 ml for each well of a six-well plate) so that it can be collected later as 'conditioned medium' .
25|
Continue culturing the neurons. If you are culturing for over a week, remove 50% of the medium after 7 d, and add the equivalent volume of fresh neuronal medium (pre-equilibrated as described above). We have found that the neurons are healthier with fewer medium changes and that they can last for up to 31 d after plating.
addition of pFFs to neurons • tIMInG ~60 min  crItIcal Perform this 5-10 d after plating neurons. 26| When neurons are 5-10 DIV, check that they are growing appropriately. If so, proceed to the subsequent steps. When PFFs are added at a later DIV (such as DIV10), aggregate formation occurs more quickly 15 . 28| Thaw the aliquot of 5 mg/ml PFFs at room temperature immediately before use.  crItIcal step Perform all the remaining steps at room temperature. Placing fibrils on ice causes their dissociation into monomers 33 .
29| Add PFFs to sterile PBS to a final concentration of 0.1 mg/ml, e.g., 10 µl in 490 µl of PBS or 20 ml in 980 µl of PBS. The minimal volume that can be used is 200 µl.
30|
Sonicate with 60 pulses at 10% power (total of 30 s, 0.5 s on, 0.5 s off)  crItIcal step Sonication with a micro probe tip sonicator is crucial (supplementary Video 1 and Fig. 2 ).
31|
Dilute sonicated PFFs or an equivalent volume of PBS as a control, into prewarmed neuronal medium as follows. . Abnormal α-syn derived from endogenous α-syn can be detected via immunofluorescence with a p-α-syn-specific antibody. These phosphorylated inclusions will not be visible when PFFs are added to α-syn knockout neurons (Fig. 4) . Alternatively, the neurons can be fixed with 4% (wt/vol) paraformaldehyde/4% (wt/vol) sucrose/1% (vol/vol) TX-100 and stained with an antibody to total α-syn. The normal, synaptic α-syn will be extracted and will not be visible, but the PFF-induced α-syn inclusions will not be extracted and will be visible by immunofluorescence (Fig. 5) . To distinguish exogenously added human PFFs from inclusions formed from endogenous α-syn, neurons can be co-stained using an antibody that is specific for human α-syn (LB509 or Syn204; both raised in mouse) and an antibody specific for p-α-syn (MJFR1, raised in rabbit; (a) Neurons were fixed in 4% (wt/vol) paraformaldehyde/4% (wt/vol) sucrose, and immunofluorescence was performed using an antibody to total α-syn (Syn1) and an antibody that recognizes the presynaptic marker VAMP2. In control PBS-treated neurons, α-syn colocalized extensively with VAMP2 at presynaptic terminals. 14 d after PFF treatment, α-syn no longer localized to the presynaptic terminal, but was found in longer serpentine aggregates in axons and skein-like filaments in the soma. Scale bar, 10 µm. (b) Neurons were fixed in 4% (wt/vol) paraformaldehyde/4% (wt/vol) sucrose/1% (vol/vol )TX-100, and immunofluorescence was performed using an antibody to total α-syn and an antibody that recognizes the neuron-specific marker NeuN. In control neurons, α-syn was completely extractable, but in PFF-treated neurons (here, 10 d after treatment) α-syn was insoluble and thus visible throughout the culture. Scale bars, 50 µm. (c) Higher-magnification image of 10 d post-PFF neurons fixed with 4% (wt/vol) paraformaldehyde/4% (wt/vol) sucrose/1% (vol/vol) TX-100 and co-stained using an antibody to total α-syn and NeuN. Scale bar, 10 µm. (d) 7 d after PFF treatment, neurons were fixed with 4% (wt/vol) paraformaldehyde/4% (wt/vol) sucrose and co-stained with antibodies specific to p-α-syn (red) and tau (green) to label axons. Scale bar, 10 µm.
Figure 6 | Visualization of exogenously added PFFs and p-α-syn aggregates formed from endogenous α-syn. Neurons were fixed 14 d after treatment with PFFs, and double immunofluorescence was performed using a rabbit antibody to p-α-syn generated in the Lee laboratory (green) 15 , as well as a mouse antibody, Syn204, which specifically recognizes the exogenously added human PFFs (red). There was minimal colocalization between the exogenous PFFs and the p-α-syn inclusions derived from endogenous α-syn. Scale bar, 50 µm.
step 33, inclusion formation
The density of the neurons has been optimized for efficient inclusion formation. The use of lower neuronal densities decreases the abundance of inclusions. In addition, as mentioned throughout the protocol, sonication with a probe tip sonicator is crucial for this protocol. Investigators who have tried bath sonicators for PFF sonication have not been as successful in generating abundant inclusions. Note that PFFs may lose activity over multiple freeze-thaw cycles. Verify that PFFs were diluted and stored correctly before adding them to neurons. In addition, our system has been optimized for primary hippocampal neurons from C57BL/6 mice or CD1 mice. Some neuronal populations may be more or less sensitive to the effects of the PFFs, and therefore it may be necessary to perform a time course and a concentration curve after PFF addition to determine the time point and concentration at which pathology is maximal.
step 34B, immunoblots p-α-Syn can sometimes be difficult to detect by immunoblotting. If this is difficult, we recommend loading as much protein as possible (≥10 µg). The use of BSA in the blocking buffer instead of milk may also be helpful. The use of lysates from α-syn knockout mice is also recommended as a control to distinguish specific bands.
• tIMInG Steps 1-6, preparation of PFFs: 7 d antIcIpateD results
Immunofluorescence
Substantial α-syn pathology is detectable 4-10 d after the addition of PFFs to primary hippocampal neurons from nontransgenic, wild-type mice by using this protocol. When immunofluorescence is performed with an antibody to total α-syn, α-syn will localize to presynaptic puncta in control neurons, and to longer serpentine aggregates that do not colocalize with presynaptic markers in PFF-treated neurons (Figs. 4 and 5) . Note that some presynaptic α-syn that has not converted to aggregates will remain, especially at early time points after PFF addition. This is why we recommend also performing TX-100 extraction. In neurons fixed with 4% (wt/vol) paraformaldehyde/4% (wt/vol) sucrose/1% (vol/vol) TX-100, there will be no staining for α-syn in the control neurons, but the aggregates will remain in TX-100-extracted PFF-treated neurons. When immunofluorescence is performed using antibodies to p-α-syn, the control neurons will show light, diffuse staining. However, the staining in the PFF-treated neurons will be substantially more intense, and discrete puncta and longer serpentine and skein-like aggregates will be apparent.
Immunoblots
When probed using an antibody against total α-syn, PBS-treated control neurons will show a band slightly above the 15-kDa band corresponding to monomeric α-syn exclusively in the TX-100-soluble fraction (Fig. 7) . After 14 d of treatment with PFFs, neuronal lysates will show reduced levels of α-syn in the TX-100-soluble fraction relative to control neuronal lysates, and an appearance of α-syn in the SDS-soluble fraction. These bands typically appear as a series of bands within the SDS fraction, probably corresponding to α-syn oligomers. PBS-treated control neurons will not show p-α-syn immunoreactivity in the TX-100 or the SDS fraction. PFF-treated neurons will show pathologic p-α-syn immunoreactivity, predominately in the SDS-soluble fraction, which again will appear as a series of bands. Figure 7 | Typical immunoblotting results seen after sequential extraction of neurons in 1% (vol/vol) TX-100 followed by SDS. (a) Immunoblotting was performed using Syn1, an antibody that recognizes total α-syn.
In control neurons, α-syn was completely extractable in TX-100. In PFF-treated neurons, there was a decrease in TX-100 soluble α-syn and an increase in SDS-soluble α-syn. (b) Immunoblots of SDS extracts (TX-100 insoluble) using mAB81a, which recognizes p-α-syn. There was no p-α-syn in control neurons, but there was a substantial amount of p-α-syn in PFF-treated neurons. The units to the left of each blot represent molecular-weight markers in kDa.
